Role of angiotensin receptor-neprilysin inhibitor in diabetic complications

doi:10.4239/wjd.v15.i5.867

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5247)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

159

WORD

HTML

2470

Figures (1-2)

503

Sum=3141

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

249

Download

851

Sum=1100

Publishing Process of This Article

Item

Count

Browse

131

Download

640

Sum=771

May 15, 2024 (publication date) through Mar 10, 2026

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. May 15, 2024; 15(5): 867-875
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.867

Role of angiotensin receptor-neprilysin inhibitor in diabetic complications

Ying Liu, Cun-Yu Lu, Yi Zheng, Yu-Min Zhang, Ling-Ling Qian, Ku-Lin Li, Gary Tse, Ru-Xing Wang, Tong Liu

Ying Liu, Yi Zheng, Gary Tse, Tong Liu, Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

Cun-Yu Lu, Department of Cardiology, Xuzhou No. 1 Peoples Hospital, Xuzhou 221005, Jiangsu Province, China

Yu-Min Zhang, Department of Cardiology, Wuxi 9^th People’s Hospital Affiliated to Soochow University, Wuxi 214062, Jiangsu Province, China

Ling-Ling Qian, Ku-Lin Li, Ru-Xing Wang, Department of Cardiology, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi 214023, Jiangsu Province, China

Gary Tse, School of Nursing and Health Studies, Metropolitan University, Hong Kong 999077, China

Gary Tse, Kent and Medway Medical School, Kent CT2 7NT, Canterbury, United Kingdom

Co-first authors: Ying Liu and Cun-Yu Lu.

Author contributions: Liu Y and Qian LL contributed to the conceptualization of this review; Zhang YM and Li KL performed the literature search; Liu Y, Lu CY, and Zheng Y drafted the work and finally; Tse G, Wang RX, and Liu T critically revised the work; and all authors have read and approved the final manuscript; Wang RX and Liu T contributed equally to this paper.

Supported by Tianjin Key Medical Discipline (Specialty) Construction Project, No. TJYXZDXK-029A; and the National Natural Science Foundation of China, No. 82370342.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Tong Liu, PhD, Professor, Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin 300211, China. liutongdoc@126.com

Received: October 8, 2023
Peer-review started: October 8, 2023
First decision: December 18, 2023
Revised: December 31, 2023
Accepted: March 25, 2024
Article in press: March 25, 2024
Published online: May 15, 2024
Processing time: 215 Days and 10.1 Hours

Abstract

Diabetes mellitus is a prevalent disorder with multi-system manifestations, causing a significant burden in terms of disability and deaths globally. Angio-tensin receptor-neprilysin inhibitor (ARNI) belongs to a class of medications for treating heart failure, with the benefits of reducing hospitalization rates and mortality. This review mainly focuses on the clinical and basic investigations related to ARNI and diabetic complications, discussing possible physiological and molecular mechanisms, with insights for future applications.

Keywords: Angiotensin receptor-neprilysin inhibitor; Diabetic mellitus; Complication

Core Tip: Diabetes mellitus is a prevalent disorder with multi-system manifestations, causing a significant burden in terms of disability and deaths globally. Angiotensin receptor-neprilysin inhibitor (ARNI) belongs to a class of medications for treating heart failure, with the benefits of reducing hospitalization rates and mortality. This review mainly focuses on the clinical and basic investigations related to ARNI and diabetic complications, discussing possible physiological and molecular mechanisms, with insights for future applications.